img

Global Primary Biliary Cirrhosis Drug Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application

Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global Primary Biliary Cirrhosis Drug Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application

Primary Biliary Cirrhosis Drug report published by QYResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Primary Biliary Cirrhosis Drug market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Demand from Clinic and Hospital are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Primary Biliary Cirrhosis Drug industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2034.
Globally, Primary Biliary Cirrhosis Drug key manufacturers include AlbireoPharma, CymaBay Therapeutics, Inc., Dr. Falk Pharma GmbH, Enanta Pharmaceuticals, Inc., GlaxoSmithKline Plc, Intercept Pharmaceuticals, Inc., Johnson & Johnson, MediGene AG and NGM Biopharmaceuticals, Inc., etc. AlbireoPharma, CymaBay Therapeutics, Inc., Dr. Falk Pharma GmbH are top 3 players and held % sales share in total in 2022.
Primary Biliary Cirrhosis Drug can be divided into Budesonide, FFP-104, GSK-2330672 and MBX-8025, etc. Budesonide is the mainstream product in the market, accounting for % sales share globally in 2022.
Primary Biliary Cirrhosis Drug is widely used in various fields, such as Clinic, Hospital and Others,, etc. Clinic provides greatest supports to the Primary Biliary Cirrhosis Drug industry development. In 2022, global % sales of Primary Biliary Cirrhosis Drug went into Clinic filed.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Primary Biliary Cirrhosis Drug market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report



By Company


AlbireoPharma
CymaBay Therapeutics, Inc.
Dr. Falk Pharma GmbH
Enanta Pharmaceuticals, Inc.
GlaxoSmithKline Plc
Intercept Pharmaceuticals, Inc.
Johnson & Johnson
MediGene AG
NGM Biopharmaceuticals, Inc.
Virobay Inc.
Segment by Type
Budesonide
FFP-104
GSK-2330672
MBX-8025
NGM-282
Others

Segment by Application


Clinic
Hospital
Others

Segment by Region


North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Primary Biliary Cirrhosis Drug market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Primary Biliary Cirrhosis Drug, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Primary Biliary Cirrhosis Drug industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Primary Biliary Cirrhosis Drug in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Primary Biliary Cirrhosis Drug introduction, etc. Primary Biliary Cirrhosis Drug Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13QYResearch’s Conclusions of Primary Biliary Cirrhosis Drug market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by QYResearch.

Table of Content

1 Primary Biliary Cirrhosis Drug Market Overview
1.1 Primary Biliary Cirrhosis Drug Product Overview
1.2 Primary Biliary Cirrhosis Drug Market Segment by Type
1.2.1 Budesonide
1.2.2 FFP-104
1.2.3 GSK-2330672
1.2.4 MBX-8025
1.2.5 NGM-282
1.2.6 Others
1.3 Global Primary Biliary Cirrhosis Drug Market Size by Type
1.3.1 Global Primary Biliary Cirrhosis Drug Market Size Overview by Type (2018-2034)
1.3.2 Global Primary Biliary Cirrhosis Drug Historic Market Size Review by Type (2018-2024)
1.3.3 Global Primary Biliary Cirrhosis Drug Forecasted Market Size by Type (2024-2034)
1.4 Key Regions Market Size Segment by Type
1.4.1 North America Primary Biliary Cirrhosis Drug Sales Breakdown by Type (2018-2024)
1.4.2 Europe Primary Biliary Cirrhosis Drug Sales Breakdown by Type (2018-2024)
1.4.3 Asia-Pacific Primary Biliary Cirrhosis Drug Sales Breakdown by Type (2018-2024)
1.4.4 Latin America Primary Biliary Cirrhosis Drug Sales Breakdown by Type (2018-2024)
1.4.5 Middle East and Africa Primary Biliary Cirrhosis Drug Sales Breakdown by Type (2018-2024)
2 Global Primary Biliary Cirrhosis Drug Market Competition by Company
2.1 Global Top Players by Primary Biliary Cirrhosis Drug Sales (2018-2024)
2.2 Global Top Players by Primary Biliary Cirrhosis Drug Revenue (2018-2024)
2.3 Global Top Players by Primary Biliary Cirrhosis Drug Price (2018-2024)
2.4 Global Top Manufacturers Primary Biliary Cirrhosis Drug Manufacturing Base Distribution, Sales Area, Product Type
2.5 Primary Biliary Cirrhosis Drug Market Competitive Situation and Trends
2.5.1 Primary Biliary Cirrhosis Drug Market Concentration Rate (2018-2024)
2.5.2 Global 5 and 10 Largest Manufacturers by Primary Biliary Cirrhosis Drug Sales and Revenue in 2022
2.6 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Primary Biliary Cirrhosis Drug as of 2022)
2.7 Date of Key Manufacturers Enter into Primary Biliary Cirrhosis Drug Market
2.8 Key Manufacturers Primary Biliary Cirrhosis Drug Product Offered
2.9 Mergers & Acquisitions, Expansion
3 Primary Biliary Cirrhosis Drug Status and Outlook by Region
3.1 Global Primary Biliary Cirrhosis Drug Market Size and CAGR by Region: 2018 VS 2022 VS 2034
3.2 Global Primary Biliary Cirrhosis Drug Historic Market Size by Region
3.2.1 Global Primary Biliary Cirrhosis Drug Sales in Volume by Region (2018-2024)
3.2.2 Global Primary Biliary Cirrhosis Drug Sales in Value by Region (2018-2024)
3.2.3 Global Primary Biliary Cirrhosis Drug Sales (Volume & Value) Price and Gross Margin (2018-2024)
3.3 Global Primary Biliary Cirrhosis Drug Forecasted Market Size by Region
3.3.1 Global Primary Biliary Cirrhosis Drug Sales in Volume by Region (2024-2034)
3.3.2 Global Primary Biliary Cirrhosis Drug Sales in Value by Region (2024-2034)
3.3.3 Global Primary Biliary Cirrhosis Drug Sales (Volume & Value), Price and Gross Margin (2024-2034)
4 Global Primary Biliary Cirrhosis Drug by Application
4.1 Primary Biliary Cirrhosis Drug Market Segment by Application
4.1.1 Clinic
4.1.2 Hospital
4.1.3 Others
4.2 Global Primary Biliary Cirrhosis Drug Market Size by Application
4.2.1 Global Primary Biliary Cirrhosis Drug Market Size Overview by Application (2018-2034)
4.2.2 Global Primary Biliary Cirrhosis Drug Historic Market Size Review by Application (2018-2024)
4.2.3 Global Primary Biliary Cirrhosis Drug Forecasted Market Size by Application (2024-2034)
4.3 Key Regions Market Size Segment by Application
4.3.1 North America Primary Biliary Cirrhosis Drug Sales Breakdown by Application (2018-2024)
4.3.2 Europe Primary Biliary Cirrhosis Drug Sales Breakdown by Application (2018-2024)
4.3.3 Asia-Pacific Primary Biliary Cirrhosis Drug Sales Breakdown by Application (2018-2024)
4.3.4 Latin America Primary Biliary Cirrhosis Drug Sales Breakdown by Application (2018-2024)
4.3.5 Middle East and Africa Primary Biliary Cirrhosis Drug Sales Breakdown by Application (2018-2024)
5 North America Primary Biliary Cirrhosis Drug by Country
5.1 North America Primary Biliary Cirrhosis Drug Historic Market Size by Country
5.1.1 North America Primary Biliary Cirrhosis Drug Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2034
5.1.2 North America Primary Biliary Cirrhosis Drug Sales in Volume by Country (2018-2024)
5.1.3 North America Primary Biliary Cirrhosis Drug Sales in Value by Country (2018-2024)
5.2 North America Primary Biliary Cirrhosis Drug Forecasted Market Size by Country
5.2.1 North America Primary Biliary Cirrhosis Drug Sales in Volume by Country (2024-2034)
5.2.2 North America Primary Biliary Cirrhosis Drug Sales in Value by Country (2024-2034)
6 Europe Primary Biliary Cirrhosis Drug by Country
6.1 Europe Primary Biliary Cirrhosis Drug Historic Market Size by Country
6.1.1 Europe Primary Biliary Cirrhosis Drug Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2034
6.1.2 Europe Primary Biliary Cirrhosis Drug Sales in Volume by Country (2018-2024)
6.1.3 Europe Primary Biliary Cirrhosis Drug Sales in Value by Country (2018-2024)
6.2 Europe Primary Biliary Cirrhosis Drug Forecasted Market Size by Country
6.2.1 Europe Primary Biliary Cirrhosis Drug Sales in Volume by Country (2024-2034)
6.2.2 Europe Primary Biliary Cirrhosis Drug Sales in Value by Country (2024-2034)
7 Asia-Pacific Primary Biliary Cirrhosis Drug by Region
7.1 Asia-Pacific Primary Biliary Cirrhosis Drug Historic Market Size by Region
7.1.1 Asia-Pacific Primary Biliary Cirrhosis Drug Market Size Growth Rate (CAGR) by Region: 2018 VS 2022 VS 2034
7.1.2 Asia-Pacific Primary Biliary Cirrhosis Drug Sales in Volume by Region (2018-2024)
7.1.3 Asia-Pacific Primary Biliary Cirrhosis Drug Sales in Value by Region (2018-2024)
7.2 Asia-Pacific Primary Biliary Cirrhosis Drug Forecasted Market Size by Region
7.2.1 Asia-Pacific Primary Biliary Cirrhosis Drug Sales in Volume by Region (2024-2034)
7.2.2 Asia-Pacific Primary Biliary Cirrhosis Drug Sales in Value by Region (2024-2034)
8 Latin America Primary Biliary Cirrhosis Drug by Country
8.1 Latin America Primary Biliary Cirrhosis Drug Historic Market Size by Country
8.1.1 Latin America Primary Biliary Cirrhosis Drug Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2034
8.1.2 Latin America Primary Biliary Cirrhosis Drug Sales in Volume by Country (2018-2024)
8.1.3 Latin America Primary Biliary Cirrhosis Drug Sales in Value by Country (2018-2024)
8.2 Latin America Primary Biliary Cirrhosis Drug Forecasted Market Size by Country
8.2.1 Latin America Primary Biliary Cirrhosis Drug Sales in Volume by Country (2024-2034)
8.2.2 Latin America Primary Biliary Cirrhosis Drug Sales in Value by Country (2024-2034)
9 Middle East and Africa Primary Biliary Cirrhosis Drug by Country
9.1 Middle East and Africa Primary Biliary Cirrhosis Drug Historic Market Size by Country
9.1.1 Middle East and Africa Primary Biliary Cirrhosis Drug Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2034
9.1.2 Middle East and Africa Primary Biliary Cirrhosis Drug Sales in Volume by Country (2018-2024)
9.1.3 Middle East and Africa Primary Biliary Cirrhosis Drug Sales in Value by Country (2018-2024)
9.2 Middle East and Africa Primary Biliary Cirrhosis Drug Forecasted Market Size by Country
9.2.1 Middle East and Africa Primary Biliary Cirrhosis Drug Sales in Volume by Country (2024-2034)
9.2.2 Middle East and Africa Primary Biliary Cirrhosis Drug Sales in Value by Country (2024-2034)
10 Company Profiles
10.1 AlbireoPharma
10.1.1 AlbireoPharma Company Information
10.1.2 AlbireoPharma Introduction and Business Overview
10.1.3 AlbireoPharma Primary Biliary Cirrhosis Drug Sales, Revenue and Gross Margin (2018-2024)
10.1.4 AlbireoPharma Primary Biliary Cirrhosis Drug Products Offered
10.1.5 AlbireoPharma Recent Development
10.2 CymaBay Therapeutics, Inc.
10.2.1 CymaBay Therapeutics, Inc. Company Information
10.2.2 CymaBay Therapeutics, Inc. Introduction and Business Overview
10.2.3 CymaBay Therapeutics, Inc. Primary Biliary Cirrhosis Drug Sales, Revenue and Gross Margin (2018-2024)
10.2.4 CymaBay Therapeutics, Inc. Primary Biliary Cirrhosis Drug Products Offered
10.2.5 CymaBay Therapeutics, Inc. Recent Development
10.3 Dr. Falk Pharma GmbH
10.3.1 Dr. Falk Pharma GmbH Company Information
10.3.2 Dr. Falk Pharma GmbH Introduction and Business Overview
10.3.3 Dr. Falk Pharma GmbH Primary Biliary Cirrhosis Drug Sales, Revenue and Gross Margin (2018-2024)
10.3.4 Dr. Falk Pharma GmbH Primary Biliary Cirrhosis Drug Products Offered
10.3.5 Dr. Falk Pharma GmbH Recent Development
10.4 Enanta Pharmaceuticals, Inc.
10.4.1 Enanta Pharmaceuticals, Inc. Company Information
10.4.2 Enanta Pharmaceuticals, Inc. Introduction and Business Overview
10.4.3 Enanta Pharmaceuticals, Inc. Primary Biliary Cirrhosis Drug Sales, Revenue and Gross Margin (2018-2024)
10.4.4 Enanta Pharmaceuticals, Inc. Primary Biliary Cirrhosis Drug Products Offered
10.4.5 Enanta Pharmaceuticals, Inc. Recent Development
10.5 GlaxoSmithKline Plc
10.5.1 GlaxoSmithKline Plc Company Information
10.5.2 GlaxoSmithKline Plc Introduction and Business Overview
10.5.3 GlaxoSmithKline Plc Primary Biliary Cirrhosis Drug Sales, Revenue and Gross Margin (2018-2024)
10.5.4 GlaxoSmithKline Plc Primary Biliary Cirrhosis Drug Products Offered
10.5.5 GlaxoSmithKline Plc Recent Development
10.6 Intercept Pharmaceuticals, Inc.
10.6.1 Intercept Pharmaceuticals, Inc. Company Information
10.6.2 Intercept Pharmaceuticals, Inc. Introduction and Business Overview
10.6.3 Intercept Pharmaceuticals, Inc. Primary Biliary Cirrhosis Drug Sales, Revenue and Gross Margin (2018-2024)
10.6.4 Intercept Pharmaceuticals, Inc. Primary Biliary Cirrhosis Drug Products Offered
10.6.5 Intercept Pharmaceuticals, Inc. Recent Development
10.7 Johnson & Johnson
10.7.1 Johnson & Johnson Company Information
10.7.2 Johnson & Johnson Introduction and Business Overview
10.7.3 Johnson & Johnson Primary Biliary Cirrhosis Drug Sales, Revenue and Gross Margin (2018-2024)
10.7.4 Johnson & Johnson Primary Biliary Cirrhosis Drug Products Offered
10.7.5 Johnson & Johnson Recent Development
10.8 MediGene AG
10.8.1 MediGene AG Company Information
10.8.2 MediGene AG Introduction and Business Overview
10.8.3 MediGene AG Primary Biliary Cirrhosis Drug Sales, Revenue and Gross Margin (2018-2024)
10.8.4 MediGene AG Primary Biliary Cirrhosis Drug Products Offered
10.8.5 MediGene AG Recent Development
10.9 NGM Biopharmaceuticals, Inc.
10.9.1 NGM Biopharmaceuticals, Inc. Company Information
10.9.2 NGM Biopharmaceuticals, Inc. Introduction and Business Overview
10.9.3 NGM Biopharmaceuticals, Inc. Primary Biliary Cirrhosis Drug Sales, Revenue and Gross Margin (2018-2024)
10.9.4 NGM Biopharmaceuticals, Inc. Primary Biliary Cirrhosis Drug Products Offered
10.9.5 NGM Biopharmaceuticals, Inc. Recent Development
10.10 Virobay Inc.
10.10.1 Virobay Inc. Company Information
10.10.2 Virobay Inc. Introduction and Business Overview
10.10.3 Virobay Inc. Primary Biliary Cirrhosis Drug Sales, Revenue and Gross Margin (2018-2024)
10.10.4 Virobay Inc. Primary Biliary Cirrhosis Drug Products Offered
10.10.5 Virobay Inc. Recent Development
11 Upstream, Opportunities, Challenges, Risks and Influences Factors Analysis
11.1 Primary Biliary Cirrhosis Drug Key Raw Materials
11.1.1 Key Raw Materials
11.1.2 Key Raw Materials Price
11.1.3 Raw Materials Key Suppliers
11.2 Manufacturing Cost Structure
11.2.1 Raw Materials
11.2.2 Labor Cost
11.2.3 Manufacturing Expenses
11.3 Primary Biliary Cirrhosis Drug Industrial Chain Analysis
11.4 Primary Biliary Cirrhosis Drug Market Dynamics
11.4.1 Primary Biliary Cirrhosis Drug Industry Trends
11.4.2 Primary Biliary Cirrhosis Drug Market Drivers
11.4.3 Primary Biliary Cirrhosis Drug Market Challenges
11.4.4 Primary Biliary Cirrhosis Drug Market Restraints
12 Market Strategy Analysis, Distributors
12.1 Sales Channel
12.2 Primary Biliary Cirrhosis Drug Distributors
12.3 Primary Biliary Cirrhosis Drug Downstream Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.2 Data Source
14.2 Author Details
14.3 Disclaimer

List of Figure

List of Tables
Table 1. Major Company of Budesonide
Table 2. Major Company of FFP-104
Table 3. Major Company of GSK-2330672
Table 4. Major Company of MBX-8025
Table 5. Major Company of NGM-282
Table 6. Major Company of Others
Table 7. Global Primary Biliary Cirrhosis Drug Sales by Type 2018 VS 2022 VS 2034 (US$ Million)
Table 8. Global Primary Biliary Cirrhosis Drug Sales by Type (2018-2024) & (K Pcs)
Table 9. Global Primary Biliary Cirrhosis Drug Sales Market Share in Volume by Type (2018-2024)
Table 10. Global Primary Biliary Cirrhosis Drug Sales by Type (2018-2024) & (US& Million)
Table 11. Global Primary Biliary Cirrhosis Drug Market Share in Value by Type (2018-2024)
Table 12. Global Primary Biliary Cirrhosis Drug Price by Type (2018-2024) & (USD/Pcs)
Table 13. Global Primary Biliary Cirrhosis Drug Sales by Type (2024-2034) & (K Pcs)
Table 14. Global Primary Biliary Cirrhosis Drug Sales Market Share in Volume by Type (2024-2034)
Table 15. Global Primary Biliary Cirrhosis Drug Sales by Type (2024-2034) & (US$ Million)
Table 16. Global Primary Biliary Cirrhosis Drug Sales Market Share in Value by Type (2024-2034)
Table 17. Global Primary Biliary Cirrhosis Drug Price by Type (2024-2034) & (USD/Pcs)
Table 18. North America Primary Biliary Cirrhosis Drug Sales by Type (2018-2024) & (K Pcs)
Table 19. North America Primary Biliary Cirrhosis Drug Sales by Type (2018-2024) & (US$ Million)
Table 20. Europe Primary Biliary Cirrhosis Drug Sales (K Pcs) by Type (2018-2024)
Table 21. Europe Primary Biliary Cirrhosis Drug Sales by Type (2018-2024) & (US$ Million)
Table 22. Asia-Pacific Primary Biliary Cirrhosis Drug Sales (K Pcs) by Type (2018-2024)
Table 23. Asia-Pacific Primary Biliary Cirrhosis Drug Sales by Type (2018-2024) & (US$ Million)
Table 24. Latin America Primary Biliary Cirrhosis Drug Sales (K Pcs) by Type (2018-2024)
Table 25. Latin America Primary Biliary Cirrhosis Drug Sales by Type (2018-2024) & (US$ Million)
Table 26. Middle East and Africa Primary Biliary Cirrhosis Drug Sales (K Pcs) by Type (2018-2024)
Table 27. Middle East and Africa Primary Biliary Cirrhosis Drug Sales by Type (2018-2024) & (US$ Million)
Table 28. Global Primary Biliary Cirrhosis Drug Sales by Company (2018-2024) & (K Pcs)
Table 29. Global Primary Biliary Cirrhosis Drug Sales Share by Company (2018-2024)
Table 30. Global Primary Biliary Cirrhosis Drug Revenue by Company (2018-2024) & (US$ Million)
Table 31. Global Primary Biliary Cirrhosis Drug Revenue Share by Company (2018-2024)
Table 32. Global Market Primary Biliary Cirrhosis Drug Price by Company (2018-2024) & (USD/Pcs)
Table 33. Global Primary Biliary Cirrhosis Drug Top Manufacturers Manufacturing Base Distribution and Sales Area
Table 34. Global Primary Biliary Cirrhosis Drug Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 35. Global Top Manufacturers Market Share by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Primary Biliary Cirrhosis Drug as of 2022)
Table 36. Date of Key Manufacturers Enter into Primary Biliary Cirrhosis Drug Market
Table 37. Key Manufacturers Primary Biliary Cirrhosis Drug Product Type
Table 38. Mergers & Acquisitions, Expansion Plans
Table 39. Global Primary Biliary Cirrhosis Drug Market Size Comparison by Region (US$ Million): 2018 VS 2022 VS 2034
Table 40. Global Primary Biliary Cirrhosis Drug Sales by Region (2018-2024) & (K Pcs)
Table 41. Global Primary Biliary Cirrhosis Drug Sales Market Share in Volume by Region (2018-2024)
Table 42. Global Primary Biliary Cirrhosis Drug Sales by Region (2018-2024) & (US$ Million)
Table 43. Global Primary Biliary Cirrhosis Drug Sales Market Share in Value by Region (2018-2024)
Table 44. Global Primary Biliary Cirrhosis Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 45. Global Primary Biliary Cirrhosis Drug Sales by Region (2024-2034) & (K Pcs)
Table 46. Global Primary Biliary Cirrhosis Drug Sales Market Share in Volume by Region (2024-2034)
Table 47. Global Primary Biliary Cirrhosis Drug Sales by Region (2024-2034) & (US$ Million)
Table 48. Global Primary Biliary Cirrhosis Drug Sales Market Share in Value by Region (2024-2034)
Table 49. Global Primary Biliary Cirrhosis Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2024-2034)
Table 50. Global Primary Biliary Cirrhosis Drug Sales by Application: 2018 VS 2022 VS 2034 (US$ Million)
Table 51. Global Primary Biliary Cirrhosis Drug Sales by Application (2018-2024) & (K Pcs)
Table 52. Global Primary Biliary Cirrhosis Drug Sales Market Share in Volume by Application (2018-2024)
Table 53. Global Primary Biliary Cirrhosis Drug Sales by Application (2018-2024) & (US$ Million)
Table 54. Global Primary Biliary Cirrhosis Drug Sales Market Share in Value by Application (2018-2024)
Table 55. Global Primary Biliary Cirrhosis Drug Price by Application (2018-2024) & (USD/Pcs)
Table 56. Global Primary Biliary Cirrhosis Drug Sales by Application (2024-2034) & (K Pcs)
Table 57. Global Primary Biliary Cirrhosis Drug Sales Market Share in Volume by Application (2024-2034)
Table 58. Global Primary Biliary Cirrhosis Drug Sales by Application (2024-2034) & (US$ Million)
Table 59. Global Primary Biliary Cirrhosis Drug Sales Market Share in Value by Application (2024-2034)
Table 60. Global Primary Biliary Cirrhosis Drug Price by Application (2024-2034) & (USD/Pcs)
Table 61. North America Primary Biliary Cirrhosis Drug Sales by Application (2018-2024) (K Pcs)
Table 62. North America Primary Biliary Cirrhosis Drug Sales by Application (2018-2024) & (US$ Million)
Table 63. Europe Primary Biliary Cirrhosis Drug Sales by Application (2018-2024) (K Pcs)
Table 64. Europe Primary Biliary Cirrhosis Drug Sales by Application (2018-2024) & (US$ Million)
Table 65. Asia-Pacific Primary Biliary Cirrhosis Drug Sales by Application (2018-2024) (K Pcs)
Table 66. Asia-Pacific Primary Biliary Cirrhosis Drug Sales by Application (2018-2024) & (US$ Million)
Table 67. Latin America Primary Biliary Cirrhosis Drug Sales by Application (2018-2024) (K Pcs)
Table 68. Latin America Primary Biliary Cirrhosis Drug Sales by Application (2018-2024) & (US$ Million)
Table 69. Middle East and Africa Primary Biliary Cirrhosis Drug Sales by Application (2018-2024) (K Pcs)
Table 70. Middle East and Africa Primary Biliary Cirrhosis Drug Sales by Application (2018-2024) & (US$ Million)
Table 71. North America Primary Biliary Cirrhosis Drug Sales by Country (2018-2024) & (K Pcs)
Table 72. North America Primary Biliary Cirrhosis Drug Sales Market Share in Volume by Country (2018-2024)
Table 73. North America Primary Biliary Cirrhosis Drug Sales by Country (2018-2024) & (US$ Million)
Table 74. North America Primary Biliary Cirrhosis Drug Sales Market Share in Value by Country (2018-2024)
Table 75. North America Primary Biliary Cirrhosis Drug Sales by Country (2024-2034) & (K Pcs)
Table 76. North America Primary Biliary Cirrhosis Drug Sales Market Share in Volume by Country (2024-2034)
Table 77. North America Primary Biliary Cirrhosis Drug Sales by Country (2024-2034) & (US$ Million)
Table 78. North America Primary Biliary Cirrhosis Drug Sales Market Share in Value by Country (2024-2034)
Table 79. Europe Primary Biliary Cirrhosis Drug Sales by Country (2018-2024) & (K Pcs)
Table 80. Europe Primary Biliary Cirrhosis Drug Sales Market Share in Volume by Country (2018-2024)
Table 81. Europe Primary Biliary Cirrhosis Drug Sales by Country (2018-2024) & (US$ Million)
Table 82. Europe Primary Biliary Cirrhosis Drug Sales Market Share in Value by Country (2018-2024)
Table 83. Europe Primary Biliary Cirrhosis Drug Sales by Country (2024-2034) & (K Pcs)
Table 84. Europe Primary Biliary Cirrhosis Drug Sales Market Share in Volume by Country (2024-2034)
Table 85. Europe Primary Biliary Cirrhosis Drug Sales by Country (2024-2034) & (US$ Million)
Table 86. Europe Primary Biliary Cirrhosis Drug Sales Market Share in Value by Country (2024-2034)
Table 87. Asia-Pacific Primary Biliary Cirrhosis Drug Sales by Region (2018-2024) & (K Pcs)
Table 88. Asia-Pacific Primary Biliary Cirrhosis Drug Sales Market Share in Volume by Region (2018-2024)
Table 89. Asia-Pacific Primary Biliary Cirrhosis Drug Sales by Region (2018-2024) & (US$ Million)
Table 90. Asia-Pacific Primary Biliary Cirrhosis Drug Sales Market Share in Value by Region (2018-2024)
Table 91. Asia-Pacific Primary Biliary Cirrhosis Drug Sales by Region (2024-2034) & (K Pcs)
Table 92. Asia-Pacific Primary Biliary Cirrhosis Drug Sales Market Share in Volume by Region (2024-2034)
Table 93. Asia-Pacific Primary Biliary Cirrhosis Drug Sales by Region (2024-2034) & (US$ Million)
Table 94. Asia-Pacific Primary Biliary Cirrhosis Drug Sales Market Share in Value by Region (2024-2034)
Table 95. Latin America Primary Biliary Cirrhosis Drug Sales by Country (2018-2024) & (K Pcs)
Table 96. Latin America Primary Biliary Cirrhosis Drug Sales Market Share in Volume by Country (2018-2024)
Table 97. Latin America Primary Biliary Cirrhosis Drug Sales by Country (2018-2024) & (US$ Million)
Table 98. Latin America Primary Biliary Cirrhosis Drug Sales Market Share in Value by Country (2018-2024)
Table 99. Latin America Primary Biliary Cirrhosis Drug Sales by Country (2024-2034) & (K Pcs)
Table 100. Latin America Primary Biliary Cirrhosis Drug Sales Market Share in Volume by Country (2024-2034)
Table 101. Latin America Primary Biliary Cirrhosis Drug Sales by Country (2024-2034) & (US$ Million)
Table 102. Latin America Primary Biliary Cirrhosis Drug Sales Market Share in Value by Country (2024-2034)
Table 103. Middle East and Africa Primary Biliary Cirrhosis Drug Sales by Country (2018-2024) & (K Pcs)
Table 104. Middle East and Africa Primary Biliary Cirrhosis Drug Sales Market Share in Volume by Country (2018-2024)
Table 105. Middle East and Africa Primary Biliary Cirrhosis Drug Sales by Country (2018-2024) & (US$ Million)
Table 106. Middle East and Africa Primary Biliary Cirrhosis Drug Sales Market Share in Value by Country (2018-2024)
Table 107. Middle East and Africa Primary Biliary Cirrhosis Drug Sales by Country (2024-2034) & (K Pcs)
Table 108. Middle East and Africa Primary Biliary Cirrhosis Drug Sales Market Share in Volume by Country (2024-2034)
Table 109. Middle East and Africa Primary Biliary Cirrhosis Drug Sales by Country (2024-2034) & (US$ Million)
Table 110. Middle East and Africa Primary Biliary Cirrhosis Drug Sales Market Share in Value by Country (2024-2034)
Table 111. AlbireoPharma Company Information
Table 112. AlbireoPharma Introduction and Business Overview
Table 113. AlbireoPharma Primary Biliary Cirrhosis Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 114. AlbireoPharma Primary Biliary Cirrhosis Drug Product
Table 115. AlbireoPharma Recent Development
Table 116. CymaBay Therapeutics, Inc. Company Information
Table 117. CymaBay Therapeutics, Inc. Introduction and Business Overview
Table 118. CymaBay Therapeutics, Inc. Primary Biliary Cirrhosis Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 119. CymaBay Therapeutics, Inc. Primary Biliary Cirrhosis Drug Product
Table 120. CymaBay Therapeutics, Inc. Recent Development
Table 121. Dr. Falk Pharma GmbH Company Information
Table 122. Dr. Falk Pharma GmbH Introduction and Business Overview
Table 123. Dr. Falk Pharma GmbH Primary Biliary Cirrhosis Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 124. Dr. Falk Pharma GmbH Primary Biliary Cirrhosis Drug Product
Table 125. Dr. Falk Pharma GmbH Recent Development
Table 126. Enanta Pharmaceuticals, Inc. Company Information
Table 127. Enanta Pharmaceuticals, Inc. Introduction and Business Overview
Table 128. Enanta Pharmaceuticals, Inc. Primary Biliary Cirrhosis Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 129. Enanta Pharmaceuticals, Inc. Primary Biliary Cirrhosis Drug Product
Table 130. Enanta Pharmaceuticals, Inc. Recent Development
Table 131. GlaxoSmithKline Plc Company Information
Table 132. GlaxoSmithKline Plc Introduction and Business Overview
Table 133. GlaxoSmithKline Plc Primary Biliary Cirrhosis Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 134. GlaxoSmithKline Plc Primary Biliary Cirrhosis Drug Product
Table 135. GlaxoSmithKline Plc Recent Development
Table 136. Intercept Pharmaceuticals, Inc. Company Information
Table 137. Intercept Pharmaceuticals, Inc. Introduction and Business Overview
Table 138. Intercept Pharmaceuticals, Inc. Primary Biliary Cirrhosis Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 139. Intercept Pharmaceuticals, Inc. Primary Biliary Cirrhosis Drug Product
Table 140. Intercept Pharmaceuticals, Inc. Recent Development
Table 141. Johnson & Johnson Company Information
Table 142. Johnson & Johnson Introduction and Business Overview
Table 143. Johnson & Johnson Primary Biliary Cirrhosis Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 144. Johnson & Johnson Primary Biliary Cirrhosis Drug Product
Table 145. Johnson & Johnson Recent Development
Table 146. MediGene AG Company Information
Table 147. MediGene AG Introduction and Business Overview
Table 148. MediGene AG Primary Biliary Cirrhosis Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 149. MediGene AG Primary Biliary Cirrhosis Drug Product
Table 150. MediGene AG Recent Development
Table 151. NGM Biopharmaceuticals, Inc. Company Information
Table 152. NGM Biopharmaceuticals, Inc. Introduction and Business Overview
Table 153. NGM Biopharmaceuticals, Inc. Primary Biliary Cirrhosis Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 154. NGM Biopharmaceuticals, Inc. Primary Biliary Cirrhosis Drug Product
Table 155. NGM Biopharmaceuticals, Inc. Recent Development
Table 156. Virobay Inc. Company Information
Table 157. Virobay Inc. Introduction and Business Overview
Table 158. Virobay Inc. Primary Biliary Cirrhosis Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 159. Virobay Inc. Primary Biliary Cirrhosis Drug Product
Table 160. Virobay Inc. Recent Development
Table 161. Key Raw Materials Lists
Table 162. Raw Materials Key Suppliers Lists
Table 163. Primary Biliary Cirrhosis Drug Market Trends
Table 164. Primary Biliary Cirrhosis Drug Market Drivers
Table 165. Primary Biliary Cirrhosis Drug Market Challenges
Table 166. Primary Biliary Cirrhosis Drug Market Restraints
Table 167. Primary Biliary Cirrhosis Drug Distributors List
Table 168. Primary Biliary Cirrhosis Drug Downstream Customers
Table 169. Research Programs/Design for This Report
Table 170. Key Data Information from Secondary Sources
Table 171. Key Data Information from Primary Sources
List of Figures
Figure 1. Primary Biliary Cirrhosis Drug Product Picture
Figure 2. Global Primary Biliary Cirrhosis Drug Market Size, 2018 VS 2022 VS 2034 (US$ Million)
Figure 3. Global Primary Biliary Cirrhosis Drug Market Size Status and Outlook (2018-2034) & (US$ Million)
Figure 4. Global Primary Biliary Cirrhosis Drug Sales Status and Outlook (2018-2034) & (K Pcs)
Figure 5. Product Picture of Budesonide
Figure 6. Global Budesonide Sales YoY Growth (2018-2034) & (K Pcs)
Figure 7. Product Picture of FFP-104
Figure 8. Global FFP-104 Sales YoY Growth (2018-2034) & (K Pcs)
Figure 9. Product Picture of GSK-2330672
Figure 10. Global GSK-2330672 Sales YoY Growth (2018-2034) & (K Pcs)
Figure 11. Product Picture of MBX-8025
Figure 12. Global MBX-8025 Sales YoY Growth (2018-2034) & (K Pcs)
Figure 13. Product Picture of NGM-282
Figure 14. Global NGM-282 Sales YoY Growth (2018-2034) & (K Pcs)
Figure 15. Product Picture of Others
Figure 16. Global Others Sales YoY Growth (2018-2034) & (K Pcs)
Figure 17. Global Primary Biliary Cirrhosis Drug Sales by Type (2018-2034) & (US$ Million)
Figure 18. Global Primary Biliary Cirrhosis Drug Sales Market Share by Type in 2022 & 2034
Figure 19. North America Primary Biliary Cirrhosis Drug Sales Market Share in Volume by Type in 2022
Figure 20. North America Primary Biliary Cirrhosis Drug Sales Market Share in Value by Type in 2022
Figure 21. Europe Primary Biliary Cirrhosis Drug Sales Market Share in Volume by Type in 2022
Figure 22. Europe Primary Biliary Cirrhosis Drug Sales Market Share in Value by Type in 2022
Figure 23. Asia-Pacific Primary Biliary Cirrhosis Drug Sales Market Share in Volume by Type in 2022
Figure 24. Asia-Pacific Primary Biliary Cirrhosis Drug Sales Market Share in Value by Type in 2022
Figure 25. Latin America Primary Biliary Cirrhosis Drug Sales Market Share in Volume by Type in 2022
Figure 26. Latin America Primary Biliary Cirrhosis Drug Sales Market Share in Value by Type in 2022
Figure 27. Middle East and Africa Primary Biliary Cirrhosis Drug Sales Market Share in Volume by Type in 2022
Figure 28. Middle East and Africa Primary Biliary Cirrhosis Drug Sales Market Share in Value by Type in 2022
Figure 29. The 5 and 10 Largest Manufacturers in the World: Market Share by Primary Biliary Cirrhosis Drug Sales in 2022
Figure 30. The 5 and 10 Largest Manufacturers in the World: Market Share by Primary Biliary Cirrhosis Drug Revenue in 2022
Figure 31. Primary Biliary Cirrhosis Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2022
Figure 32. Product Picture of Clinic
Figure 33. Global Clinic Sales YoY Growth (2018-2034) & (K Pcs)
Figure 34. Product Picture of Hospital
Figure 35. Global Hospital Sales YoY Growth (2018-2034) & (K Pcs)
Figure 36. Product Picture of Others
Figure 37. Global Others Sales YoY Growth (2018-2034) & (K Pcs)
Figure 38. Global Primary Biliary Cirrhosis Drug Sales by Application (2018-2034) & (US$ Million)
Figure 39. Global Primary Biliary Cirrhosis Drug Sales Market Share by Application in 2022 & 2034
Figure 40. North America Primary Biliary Cirrhosis Drug Sales Market Share in Volume by Application in 2022
Figure 41. North America Primary Biliary Cirrhosis Drug Sales Market Share in Value by Application in 2022
Figure 42. Europe Primary Biliary Cirrhosis Drug Sales Market Share in Volume by Application in 2022
Figure 43. Europe Primary Biliary Cirrhosis Drug Sales Market Share in Value by Application in 2022
Figure 44. Asia-Pacific Primary Biliary Cirrhosis Drug Sales Market Share in Volume by Application in 2022
Figure 45. Asia-Pacific Primary Biliary Cirrhosis Drug Sales Market Share in Value by Application in 2022
Figure 46. Latin America Primary Biliary Cirrhosis Drug Sales Market Share in Volume by Application in 2022
Figure 47. Latin America Primary Biliary Cirrhosis Drug Sales Market Share in Value by Application in 2022
Figure 48. Middle East and Africa Primary Biliary Cirrhosis Drug Sales Market Share in Value by Application in 2022
Figure 49. Key Raw Materials Price
Figure 50. Primary Biliary Cirrhosis Drug Manufacturing Cost Structure
Figure 51. Primary Biliary Cirrhosis Drug Industrial Chain Analysis
Figure 52. Channels of Distribution
Figure 53. Distributors Profiles
Figure 54. Bottom-up and Top-down Approaches for This Report
Figure 55. Data Triangulation
Figure 56. Key Executives Interviewed

Select User License

$4200 Single Licence
$6000 Enterprise Licence
$9100 Corporate Licence
Note : All prices in USD

FAQ'S

User License?

For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:

sales@mraccuracyreports.com

Within 24 to 48 hrs.

You can contact Sales team (sales@mraccuracyreports.com) and they will direct you on email

You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.

Discounts are available.

Hard Copy

Email

Top Industries